Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on February 07, 2023 for Arun Kumar Pillai & Aditya Arun Kumar Strides Pharma Science Ltd - 532531 - Outcome Of The Extraordinary General Meeting Of The Company Held On February 6, 2023
Outcome of the Extraordinary General Meeting of the Company held on February 6, 2023 Strides Pharma Science Ltd - 532531 - Proceedings Of Extraordinary General Meeting (EGM) Of The Company
We wish to inform you that EGM of the Company was held on Monday, February 6, 2023 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of EGM. Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on February 01, 2023 for Shasun Leasing and Finance Pvt Ltd Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on February 01, 2023 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Sub: Earnings Call transcript pertaining to Unaudited Financial Results for the quarter and nine months ended December 31, 2022. Ref: Earning Call held on January 24, 2023 pertaining to Unaudited Financial Results for the quarter and nine months ended December 31, 2022.
Buy Strides Pharma Sciences, target of Rs 450: Sharekhan
Sharekhan is bullish on Strides Pharma Sciences has recommended buy rating on the stock with a target price of Rs 450 in its research report dated January 25, 2023. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Unaudited Financial Results for the quarter and nine months ended December 31, 2022 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings call pertaining to the Financial Results for the quarter and nine months ended December 31, 2022
